HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IFF reorganization

This article was originally published in The Rose Sheet

Executive Summary

International Flavors & Fragrances will record a nonrecurring pre-tax charge of approximately $20 mil. ($13 mil. after tax) in the first quarter as a result of employee terminations, company reports April 3. IFF recently eliminated over 150 positions primarily in North America and Europe as part of reorganization effort expected to be completed later this year. IFF revealed its reorganization plan aimed at saving approximately $25 mil.-$30 mil. annually in 2000 (1"The Rose Sheet" Oct. 9, 2000, p. 5). At the time of the announcement, IFF expected to incur $90 mil.-$100 mil. in related costs, but the fragrance supplier now anticipates charges of approximately $110 mil. Company expects to report first quarter sales up 5%-6% in line with earlier guidance...

You may also be interested in...



IFF Reorganization Plan To Save $25 Mil.-$30 Mil. By 2003, CEO Predicts

International Flavors & Fragrances will generate annual savings of $25 mil.-$30 mil. by 2003 under a reorganization plan detailed by CEO Richard Goldstein during an analyst conference call Oct. 5.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

UsernamePublicRestriction

Register

RS011103

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel